Press Room

    Back

    Press Release - October 29, 2002

    PSC Fertility Monitor Success Story Profile The First In A Series


    Pheromone Sciences Corp (TSX:PHS), is pleased to announce a Toronto based Success Story about a pregnancy resulting from the use of the PSC Fertility Monitor as a timing aid in identifying the conception or fertility window.

    The Brenda and Marcus Story as reported to Pheromone Sciences: "As a couple we lead a very active life. Marcus is a marathon runner and is frequently out training for hours each evening. I am 36 years old and also work full- time. We are a very active family, always enjoying the outdoors and participating in our daughter's life fully.

    In November 2001, Marcus and I decided to try and conceive a second child. Everyone mentioned to us that it would take only a month or two since we had previously had a child. After six months had passed by, my doctor was becoming concerned about my age and an irregular and long menstrual cycle (39 days) and the possible factor that as Marcus is an avid marathon runner, there might be some impact on his sperm count. He mentioned that our chances for a conception seemed slim without the use of fertility drugs. We decided at the time not to turn to the fertility drugs and allow nature to take its course.

    A friend mentioned the new Fertility Monitor product from Pheromone Sciences. As it seemed very easy and simple to use, I decided to give it a try. The watch-like monitor allowed me to continue a normal life without the use of medications or any methods of ovulation detection. I set up the monitor (watch) to coincide with my menstrual cycle and began wearing it as soon as my monthly cycle began in order to determine the most fertile time in my cycle. I wore the watch every night until it told me when my most fertile six days were. The rest is history.

    Within the first month of using the PSC Fertility Monitor I became pregnant. I am due this coming March. The fact that I could easily slip the watch on every night without being concerned about trying to take and interpret basal body temperatures each morning or using the very expensive and inconvenient LH test strips (I tried all these to no avail) made my life and my family's so much better and less stressful. I was able to concentrate on other aspects of my life and not worry about the fertile days in my cycle. The watch was able to help us achieve our conception goal by identifying the complete 6 days of the fertility window for us.

    I would recommend the PSC Fertility Monitor to anyone who is trying to conceive." said Brenda.

    "We are very happy to pass on knowledge of Brenda's and Marcus' success in achieving their conception goals by using our product, the PSC Fertility Monitor", said Christopher Neuman, President and CEO of Pheromone Sciences. "We welcome the news from others who have had or will have a similar experience."

    Since the FDA product approval was announced, Pheromone Sciences has opened the site www.fertiliteov.com for couples seeking to purchase this new product.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

    INVESTOR CONTACT Lorne Woods 1-(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

    Back



    Press Releases from:

    2017 2016 2015 2014 2013 2012 2011

    2010 2009 2008 2007 2006 2005 2004

    2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs

    Link

    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance

    PDF

    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario

    Link

    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Publisher: StockInterview.com
    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Publisher: StockInterview.com
    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Publisher: StockInterview.com
    Author: James Finch

    Presentation and Video

    September 11, 2017

    Sernova Fact Sheet

    September 11, 2017

    Sernova's 2017 Corporate Presentation

    PDF Presentation

    Subscribe to Sernova News

Subscribe to our News Dispatch Service

* indicates required




Latest Video and Presentation


Sernova Fact Sheet - / September 11, 2017 Open


Sernova's 2017 Corporate Presentation - PDF Presentation / September 11, 2017 Open

All Presentations →